Ocugen merger agreement with Carisma terminated due to funding shortfall
NegativeFinancial Markets

Ocugen's recent merger agreement with Carisma has been terminated due to a significant funding shortfall. This development is concerning as it highlights the financial challenges that can arise in the biotech sector, potentially impacting future collaborations and innovations. Investors and stakeholders will be watching closely to see how Ocugen navigates this setback and what it means for their pipeline and market position.
— Curated by the World Pulse Now AI Editorial System